Search

Your search keyword '"Lorenza Greco"' showing total 4 results
Start Over Author "Lorenza Greco"
4 results on '"Lorenza Greco"'

1. RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer

Author

Caterina De Luca, Francesco Pepe, Antonino Iaccarino, Pasquale Pisapia, Luisella Righi, Angela Listì, Lorenza Greco, Gianluca Gragnano, Severo Campione, Gianfranco De Dominicis, Fabio Pagni, Roberta Sgariglia, Mariantonia Nacchio, Rossella Tufano, Floriana Conticelli, Elena Vigliar, Claudio Bellevicine, Diego Luigi Cortinovis, Silvia Novello, Miguel Angel Molina-Vila, Rafael Rosell, Giancarlo Troncone, and Umberto Malapelle

Subjects
predictive molecular pathology, next generation sequencing, gene fusions, targeted therapy, NSCLC, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Gene fusions represent novel predictive biomarkers for advanced non-small cell lung cancer (NSCLC). In this study, we validated a narrow NGS gene panel able to cover therapeutically-relevant gene fusions and splicing events in advanced-stage NSCLC patients. To this aim, we first assessed minimal complementary DNA (cDNA) input and the limit of detection (LoD) in different cell lines. Then, to evaluate the feasibility of applying our panel to routine clinical samples, we retrospectively selected archived lung adenocarcinoma histological and cytological (cell blocks) samples. Overall, our SiRe RNA fusion panel was able to detect all fusions and a splicing event harbored in a RNA pool diluted up to 2 ng/µL. It also successfully analyzed 46 (95.8%) out of 48 samples. Among these, 43 (93.5%) out of 46 samples reproduced the same results as those obtained with conventional techniques. Intriguingly, the three discordant results were confirmed by a CE-IVD automated real-time polymerase chain reaction (RT-PCR) analysis (Easy PGX platform, Diatech Pharmacogenetics, Jesi, Italy). Based on these findings, we conclude that our new SiRe RNA fusion panel is a valid and robust tool for the detection of clinically relevant gene fusions and splicing events in advanced NSCLC.

Published
2021
Full Text
View/download PDF

2. RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer

Author

Fabio Pagni, Caterina De Luca, Diego Cortinovis, Silvia Novello, Luisella Righi, Roberta Sgariglia, Miguel Angel Molina-Vila, Lorenza Greco, Floriana Conticelli, Gianfranco De Dominicis, Pasquale Pisapia, Antonino Iaccarino, Claudio Bellevicine, Angela Listì, Rossella Tufano, Francesco Pepe, Elena Vigliar, Giancarlo Troncone, Umberto Malapelle, Rafael Rosell, Gianluca Gragnano, Severo Campione, Mariantonia Nacchio, De Luca, C, Pepe, F, Iaccarino, A, Pisapia, P, Righi, L, Listì, A, Greco, L, Gragnano, G, Campione, S, De Dominicis, G, Pagni, F, Sgariglia, R, Nacchio, M, Tufano, R, Conticelli, F, Vigliar, E, Bellevicine, C, Cortinovis, D, Novello, S, Molina-Vila, M, Rosell, R, Troncone, G, Malapelle, U, De Luca, Caterina, Pepe, Francesco, Iaccarino, Antonino, Pisapia, Pasquale, Righi, Luisella, Listì, Angela, Greco, Lorenza, Gragnano, Gianluca, Campione, Severo, De Dominicis, Gianfranco, Pagni, Fabio, Sgariglia, Roberta, Nacchio, Mariantonia, Tufano, Rossella, Conticelli, Floriana, Vigliar, Elena, Bellevicine, Claudio, Cortinovis, Diego Luigi, Novello, Silvia, Molina-Vila, Miguel Angel, Rosell, Rafael, Troncone, Giancarlo, and Malapelle, Umberto

Subjects
0301 basic medicine, Cancer Research, Computational biology, NSCLC, gene fusions, next generation sequencing, predictive molecular pathology, targeted therapy, Biology, lcsh:RC254-282, Article, DNA sequencing, law.invention, 03 medical and health sciences, 0302 clinical medicine, law, Complementary DNA, medicine, Lung cancer, Gene, Polymerase chain reaction, gene fusion, RNA, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 030104 developmental biology, Oncology, NGS, 030220 oncology & carcinogenesis, RNA splicing, Adenocarcinoma
Abstract

Gene fusions represent novel predictive biomarkers for advanced non-small cell lung cancer (NSCLC). In this study, we validated a narrow NGS gene panel able to cover therapeutically-relevant gene fusions and splicing events in advanced-stage NSCLC patients. To this aim, we first assessed minimal complementary DNA (cDNA) input and the limit of detection (LoD) in different cell lines. Then, to evaluate the feasibility of applying our panel to routine clinical samples, we retrospectively selected archived lung adenocarcinoma histological and cytological (cell blocks) samples. Overall, our SiRe RNA fusion panel was able to detect all fusions and a splicing event harbored in a RNA pool diluted up to 2 ng/&micro, L. It also successfully analyzed 46 (95.8%) out of 48 samples. Among these, 43 (93.5%) out of 46 samples reproduced the same results as those obtained with conventional techniques. Intriguingly, the three discordant results were confirmed by a CE-IVD automated real-time polymerase chain reaction (RT-PCR) analysis (Easy PGX platform, Diatech Pharmacogenetics, Jesi, Italy). Based on these findings, we conclude that our new SiRe RNA fusion panel is a valid and robust tool for the detection of clinically relevant gene fusions and splicing events in advanced NSCLC.

Published
2021

3. KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting

Author

Lorenza Greco, Antonio Russo, Caterina De Luca, Roberta Sgariglia, Giancarlo Troncone, Ilaria Migliatico, Valerio Gristina, Pasquale Pisapia, Eduardo Clery, Umberto Malapelle, Claudio Bellevicine, Mariantonia Nacchio, Elena Vigliar, Francesco Pepe, Nacchio, M., Sgariglia, R., Gristina, V., Pisapia, P., Pepe, F., de Luca, C., Migliatico, I., Clery, E., Greco, L., Vigliar, E., Bellevicine, C., Russo, A., Troncone, G., Malapelle, U., Nacchio M., Sgariglia R., Gristina V., Pisapia P., Pepe F., de Luca C., Migliatico I., Clery E., Greco L., Vigliar E., Bellevicine C., Russo A., Troncone G., and Malapelle U.

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, AMG510, Settore MED/06 - Oncologia Medica, Viral Oncogene, medicine.disease_cause, 03 medical and health sciences, Basal (phylogenetics), 0302 clinical medicine, G12C, Medicine, Epidermal growth factor receptor, Liquid biopsy, Lung cancer, neoplasms, Mutation, biology, business.industry, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS), Review Article on Improving Outcomes in Lung Cancer Through Early Diagnosis and Smoking Cessation, medicine.disease, Basal setting, 030104 developmental biology, Next generation sequencing (NGS), 030220 oncology & carcinogenesis, Cancer research, biology.protein, Biomarker (medicine), KRAS, business
Abstract

In advanced stage non-small cell lung cancer (NSCLC) patients, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) testing may soon acquire a predictive significance to select patients for AMG510 treatment. Since tissue samples are not always available, liquid biopsy may represent a viable option for KRAS testing. Here, we review the last three years clinical practice performed on 194 plasma based liquid biopsies by next generation sequencing (NGS) SiRe(®) panel. In particular, 36 (18.6%) KRAS mutated cases were identified, with an overall median allelic frequency of 5.0% (ranging between 0.2% and 46.8%). No concomitant mutations were observed in the other NSCLC clinical relevant genes included in the SiRe(®) panel, such as epidermal growth factor receptor (EGFR) and v-Raf murine sarcoma viral oncogene homolog B (BRAF). Exon 2 p.G12C was the most common detected mutation (13/36, 36.1%). In conclusion, our data update and confirm that SiRe(®) NGS panel represents a robust analytical tool to assess KRAS mutational status on circulating tumor DNA. Further investigation is required to design more cost-effective diagnostic algorithms to harmonize clinical relevant biomarker testing on tissue and blood in advanced stage NSCLC clinical practice.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results